CLRB241220P2500
- 2.45
- 0.000.00%
Cellectar BioSciences Newsroom
Catalyst Watch: FOMC Meeting, Govt. Funding Drama, Earnings for Micron, Nike, and FedEx
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Cellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut
Cellectar Biosciences Cut to Perform From Outperform by Oppenheimer
Cellectar Biosciences Analyst Ratings
Nasdaq Surges Over 1%; US Inflation Rises In-Line With Expectations
Oppenheimer Downgrades Cellectar BioSciences(CLRB.US) to Hold Rating
Express News | Cellectar Biosciences Inc - Estimates to Incur Severance Costs of Approximately $1.7 Million
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
Cellectar Stock Plunges 50% Post-market on Restructuring News
Cellectar Biosciences Trading Resumes
Cellectar Biosciences Evaluates Strategic Options for Iopofosine I 131 Amid Pipeline Focus Shift to Radiotherapeutics
Cellectar Biosciences: Anticipates Implementation of the Restructuring Will Extend Its Cash Runway Into 3Q 2025 >CLRB
Cellectar Biosciences: Focusing on Advancing Radiotherapeutic Assets Including Alpha- and Auger-Emitting Radioconjugates Into Phase 1 Solid Tumor Studies >CLRB
Cellectar Biosciences: Strategic Reprioritization Will Impact All Departments >CLRB
Cellectar Biosciences Reports Strategic Reprioritization, Reduces Headcount 60%
Express News | Cellectar Biosciences Inc - to Advance Clr 121225 and Clr 121125 Into Clinic
Express News | Cellectar Biosciences Inc - to Reduce Headcount by Approximately 60% by End of Q4 2024
Express News | Cellectar Biosciences Inc - to Pursue Strategic Options for Iopfosine I 131 Development
Press Release: Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring